Faeth Therapeutics
FTH
24.16
-0.76
-3.05%
Faeth Therapeutics
US · FTH
#3576 by market cap
Listed 2021
24.16
-0.76
-3.05%
Live - 5344 symbols - heartbeat 503s ago
· 2026-10-08 09:58
Pre-market
25.12
+0.80%
After-hours
24.92
0.00%
- Market cap
- 624.30M
- P/E (TTM)i
- -0.40
- P/Bi
- 3.61
- EPSi
- -16.72
- Div yieldi
- 0.00%
- 52W posi
- 48%
Reader sentiment
Are you bullish or bearish on FTH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 66.02% -0.02pp
- Institutions
- 51
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund45.40%
VC/PE Fund17.42%
Individual/Insider4.27%
Mutual Fund2.15%
Private Company0.67%
Family Office/Trust0.31%
Other29.72%
Top holders as of 2026-06-15
Khosla Ventures, LLC
10.19% · 2.63M sh
Montanova Capital, LLC
7.82% · 2.02M sh
Avoro Capital Advisors LLC
5.59% · 1.44M sh
Baker Bros. Advisors LP
4.98% · 1.29M sh
Balyasny Asset Management L.P.
4.03% · 1.04M sh
Cormorant Asset Management, LP
3.98% · 1.03M sh
Anand Parikh
3.16% · 817.70K sh
RA Capital Management, L.P.
2.79% · 722.02K sh
Fairmount Funds Management LLC
2.79% · 722.02K sh
Logos Global Management, L.P.
2.79% · 722.02K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Khosla Ventures, LLC | -- | 10.19% |
| Anand Parikh | Chief Operating Officer | 3.16% |
| James Peyer | Independent Director | 0.50% |
| Brian Stephenson | Chief Financial Officer | 0.18% |
| Stephen Hahn | Director | 0.17% |
| Karen Vousden | Scientific Co-Founder | 0.16% |
| Thomas Ricks | Independent Director | 0.07% |
| Robert Holmen | Independent Director | 0.00% |
| John Celebi | Chief Executive Officer | 0.00% |
| Christopher Gerry | General Counsel | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-10 | Karen Vousden | Scientific Co-Founder | Other Derivative Acquisition | +25,000 | $37.44 |
| 2026-09-10 | Karen Vousden | Scientific Co-Founder | Initial Statement of Beneficial | 0 | -- |
| 2026-07-21 | Cambrian BioPharma, Inc. | -- | Intent to Sell (Form 144) | -130,142 | $27.99 |
| 2026-07-20 | Anand Parikh | Chief Operating Officer | Other Derivative Acquisition | +398,018 | $28.37 |
| 2026-07-20 | Josiah Craver | Officer | Other Derivative Acquisition | +30,824 | $28.37 |
| 2026-06-30 | Brian Stephenson | Chief Financial Officer | Open Market Acquisition | +13,634 | $22.95–24.98 |
| 2026-06-25 | Brian Stephenson | Chief Financial Officer | Open Market Acquisition | +15,641 | $23.61–27.77 |
| 2026-06-22 | Brian Stephenson | Chief Financial Officer | Open Market Acquisition | +17,413 | $20.23–25.91 |
| 2026-06-21 | Anand Parikh | Chief Operating Officer | Open Market Acquisition | +2,806 | $19.76 |
| 2026-06-21 | Anand Parikh | Chief Operating Officer | Derivative Exercise and Retained | +53,465 | $1.16 |
| 2026-06-14 | Khosla Ventures, LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-06-14 | Stephen Hahn | Director | Derivative Exercise and Retained | +44,763 | -- |
| 2026-06-14 | Anand Parikh | Chief Operating Officer | Derivative Exercise and Retained | +761,428 | -- |
| 2026-06-12 | Brian Stephenson | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-06-11 | Sona Saira Ramasastry | Director | Other Derivative Acquisition | +25,000 | $13.00 |
| 2026-06-11 | Sona Saira Ramasastry | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-11 | Stephen Hahn | Director | Other Derivative Acquisition | +25,000 | $13.00 |
| 2026-06-11 | Stephen Hahn | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-09 | Robert Holmen | Independent Director | Other Derivative Acquisition | +12,500 | $11.41 |
| 2026-06-09 | Phillip Donenberg | Director | Other Derivative Acquisition | +12,500 | $11.41 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:58:46 · For reference only, not investment advice and not tailored to your situation.